ClinicalTrials.gg
CompletedNCT07812688Updated Sep 10, 2026

Effects of Allicin Pretreatment on Anti-oxidation Ability and Delayed Onset Muscle Soreness

An interventional study of allicin and placebo in Delayed Onset Muscle Soreness, sponsored by Guangxi Normal University. Completed at 1 site in China. Open to male participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Guangxi Normal University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Apr 2024, registered Sep 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
Male
01

Study summary

To investigate the effects of allicin pretreatment on delayed onset muscle soreness (DOMS), muscle function, and oxidative stress following eccentric exercise

02

Conditions studied

  • Delayed Onset Muscle Soreness

Browse trials for

03

In context

Myalgia

256 studies on the registry are indexed under Myalgia; 46 are open to participants now.

This study's enrollment of 30 is below the median of 44 across 216 interventional studies indexed under Myalgia.

Browse Myalgia studies →

Lead sponsor

Guangxi Normal University is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants voluntarily agreed to join the study and signed forms.
  • Male participants aged between 18 and 24 years.
  • Physically healthy, with no history of major or congenital diseases.
  • Normal results in routine physical examinations, with no history of severe musculoskeletal injuries.
  • Physical fitness levels equivalent to those of typical university students majoring in sports.
  • During the entire experiment, participants must not engage in any intense physical activities other than the specified exercise protocol.

Exclusion criteria

Exclusion Criteria:

  • Participants with poor compliance or those who violate the experimental requirements.
  • Participants who are unwilling to cooperate and fail to complete the required data collection for the experiment.
  • Participants who have taken anti-inflammatory or medications within the past month.
  • Participants who have experienced musculoskeletal injuries within the past two months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    allicin group

    The allicin group received garlic extract as an intervention

    Drug: allicin

  • Placebo comparator
    placebo group

    The placebo group received a placebo

    Drug: placebo

Interventions

  • Drugallicin

    The garlic extract capsules were purchased from Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. (National Drug Approval No. H32025683). Subjects took garlic extract capsules orally every day for 15 days before exercise, once per day, 4 capsules each time, equivalent to 80 mg/d

  • Drugplacebo

    The placebo was made by filling empty capsules with starch. The two were identical in packaging, appearance, color, and taste. Group B: Subjects took the same dose of placebo (starch capsules) at 80 mg/d during the same period.

06

What researchers measure

Primary outcomes

  1. Subjective Pain Sensation

    Subjective pain sensation was assessed using the Visual Analog Scale (VAS), which ranges from 0 mm (no pain) to 100 mm (worst imaginable pain). Higher scores indicate a worse outcome (greater pain intensity). Measurements were taken to evaluate the degree of Delayed Onset Muscle Soreness (DOMS) at the following time points: pre-medication (Pre-drug), pre-exercise (Pre-exercise), immediately post-exercise (Post-exercise), 24 hours post-exercise (24 h), 48 hours post-exercise (48 h), and 72 hours post-exercise (72 h).

    Time frame: Pre-medication, pre-exercise, immediately post-exercise, 24 hours, 48 hours, and 72 hours post-exercise.

Secondary outcomes

  1. Calf Circumference

    Bilateral calf circumference was measured using a soft measuring tape (Hoechstmass, Germany) at the following time points: before medication (Pre-drug), before exercise (Pre-exercise), immediately after exercise (Post-exercise), 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise. Subjects lay prone on the examination table with legs slightly abducted and knees extended. The tape was placed horizontally around the thickest part of each calf, and the circumference was recorded in centimeters (cm). Each side was measured three times, and the average value was used for analysis.

    Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

  2. Vertical Jump Height

    A vertical jump tester was used to measure the vertical jump height of the subjects at Pre-drug, Pre-exercise, Post-exercise, 24 h, 48 h, and 72 h. Subjects stood naturally on the jump platform with feet slightly apart, ready for testing. When "0.0" appeared on the screen of the electronic vertical jump platform (Hongkangda Sports Technology Development Co., Ltd., Beijing), and the subject heard "start," the test officially began. The subject bent their knees into a half-squat, swung their arms back, and forcefully jumped vertically upward. When the subject landed back on the platform, the display showed the corresponding value. The test was repeated three times, with the highest value taken.

    Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

  3. Posterior Calf Muscle Strength

    The MicroFET2 handheld muscle strength tester (Hoggan, USA) was used to measure the posterior calf muscle strength of subjects at Pre-drug, Pre-exercise, Post-exercise, 24 h, 48 h, and 72 h. The subjects were in a prone position with arms placed at the sides, and the legs bent at 60° during the initial measurement. The tester placed the device under the Achilles tendon, and the subject resisted by flexing the calf for 8 seconds, then returned to the initial position. Each leg's muscle strength was tested five times, with the highest value recorded.

    Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

  4. Knee Joint Range of Motion

    A goniometer (Changzhou Youbang Medical Rehabilitation Equipment Co., Ltd.) was used to measure the bilateral knee joint range of motion (ROM) in flexion at Pre-drug, Pre-exercise, Post-exercise, 24 h, 48 h, and 72 h. Subjects were prone (with hips and knees extended) on the edge of the examination bed, exposing the knee joint. The tester placed the axis of the goniometer at the fibular head of the knee joint, aligning the stationary arm parallel to the femoral shaft and the moving arm parallel to the fibular shaft. The moving arm followed the motion of the fibula, and the value of the knee joint's ROM was read at the terminal position

    Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

  5. Biochemical Index Sample Collection and Testing

    At Pre-drug, Pre-exercise, post-exercise, 24 h, 48 h, and 72 h, 4 ml of median cubital vein blood was collected from each subject into an anticoagulant tube. The sample was centrifuged using a benchtop high-speed centrifuge (temperature: 4°C, 1000 rpm/min) for 15 minutes, and the supernatant was transferred to an EP tube and stored at -80°C for further testing. The thiobarbituric acid (TBA) method was used to measure the MDA content, while the T-AOC was determined using the ferric ion reducing/antioxidant power (FRAP) assay. The activity of CK-MM was measured by Enzyme-Linked Immunosorbent Assay (ELISA), and CK (Creatine Kinase) activity was measured using an optimized DGK colorimetric method. The MDA, T-AOC, and CK assay kits were purchased from Nanjing Jiancheng Bioengineering Institute, and the CK-MM assay kit was obtained from CUSABIO® (Wuhan Huamei Bioengineering Co., Ltd.).

    Time frame: Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

07

Study locations

1 site
  • Guangxi Normal University
    Guilin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jun 2024, 2 months.

Of 101 non-industry interventional studies with no phase under Myalgia, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 111 studies reached it within 8 months; a quarter within 3 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 10, 2026
StartActual
Apr 1, 2024
Primary completionActual
Jun 30, 2024
CompletionActual
Jun 30, 2024
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07812688
Lead sponsor
Guangxi Normal University
Responsible party
Jingzhi Zhang (Senior Technician, Guangxi Normal University) — Principal investigator
First posted
Sep 10, 2026
Start date
Apr 1, 2024
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024
Last update
Sep 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion